Reproxalap was previously found to be statistically superior to vehicle for the primary endpoint of ocular discomfort (P=0.004) in a Phase 3 randomized, double-masked, vehicle-controlled dry eye chamber clinical trial.
Rob Sambursky, MD, president of Verséa Ophthalmics, sat down with David Hutton of Ophthalmology Times to discuss 3 major developments in the company pipeline.